Insomnia treatment long depended on GABA-acting hypnotics carrying dependence and next-day impairment concerns. Quviviq (daridorexant) belongs to the newer orexin-targeting generation designed around those issues.
As a dual orexin receptor antagonist, it blocks the wake-promoting orexin signal rather than broadly sedating the central nervous system, and its half-life was selected to limit residual morning effects. The tablet is taken once nightly for insomnia marked by difficulty with sleep onset or sleep maintenance.
Quviviq is a Schedule IV controlled substance with no generic competition, competing against suvorexant, lemborexant, and inexpensive generic z-drugs. Its differentiation rests on next-day performance data, making payer step-therapy policy the principal barrier to uptake.
